Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial of weekly nab-paclitaxel as second- or third-line treatment in patients with advanced non-small-cell lung cancer (OLCSG1303)

Trial Profile

Phase I/II trial of weekly nab-paclitaxel as second- or third-line treatment in patients with advanced non-small-cell lung cancer (OLCSG1303)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Dec 2017 Status changed from recruiting to completed.
    • 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
    • 12 Sep 2017 Primary endpoint (Objective clinical response rate) has not been met, according to results presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top